Equity Overview
Price & Market Data
Price: $3.64
Daily Change: +$0.05 / 1.37%
Daily Range: $3.55 - $3.74
Market Cap: $34,148,092
Daily Volume: 36,487
Performance Metrics
1 Week: -2.15%
1 Month: -22.55%
3 Months: -11.65%
6 Months: -86.46%
1 Year: -76.30%
YTD: -15.35%
Company Details
Employees: 10
Sector: Health technology
Industry: Biotechnology
Country:
Details
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.